DE3686811D1 - Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren. - Google Patents

Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.

Info

Publication number
DE3686811D1
DE3686811D1 DE8686904562T DE3686811T DE3686811D1 DE 3686811 D1 DE3686811 D1 DE 3686811D1 DE 8686904562 T DE8686904562 T DE 8686904562T DE 3686811 T DE3686811 T DE 3686811T DE 3686811 D1 DE3686811 D1 DE 3686811D1
Authority
DE
Germany
Prior art keywords
tumors
malignal
composition
compositions
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686904562T
Other languages
English (en)
Inventor
Gary R Landucci
Toni N Mariani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3686811D1 publication Critical patent/DE3686811D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE8686904562T 1985-06-28 1986-06-26 Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren. Expired - Lifetime DE3686811D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75009185A 1985-06-28 1985-06-28
PCT/US1986/001348 WO1987000054A1 (en) 1985-06-28 1986-06-26 Process and composition for treatment of cancer and non-malignant tumors

Publications (1)

Publication Number Publication Date
DE3686811D1 true DE3686811D1 (de) 1992-10-29

Family

ID=25016458

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686904562T Expired - Lifetime DE3686811D1 (de) 1985-06-28 1986-06-26 Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.

Country Status (13)

Country Link
EP (1) EP0227809B1 (de)
JP (1) JPS62503144A (de)
CN (1) CN86104913A (de)
AT (1) ATE80802T1 (de)
AU (1) AU597265B2 (de)
CA (1) CA1341303C (de)
DE (1) DE3686811D1 (de)
DK (1) DK107787A (de)
ES (1) ES8800981A1 (de)
HU (1) HUT43495A (de)
IL (1) IL79260A (de)
WO (1) WO1987000054A1 (de)
ZA (1) ZA864769B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1999053027A1 (en) * 1998-04-09 1999-10-21 I.D.M. Immuno-Designed Molecules Use of monocytes derived cells and antibodies in a synergic way for optimal induction of immunotherapeutic efficiency
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
US6868665B2 (en) 2001-12-21 2005-03-22 General Electric Company Methods and apparatus for operating gas turbine engines
US7200538B2 (en) 2003-01-15 2007-04-03 General Electric Company Methods and apparatus for modeling gas turbine engines

Also Published As

Publication number Publication date
IL79260A0 (en) 1986-09-30
ES8800981A1 (es) 1987-12-01
HUT43495A (en) 1987-11-30
CA1341303C (en) 2001-10-09
AU6125486A (en) 1987-01-30
CN86104913A (zh) 1987-05-27
ES556684A0 (es) 1987-12-01
WO1987000054A1 (en) 1987-01-15
AU597265B2 (en) 1990-05-31
DK107787D0 (da) 1987-03-02
EP0227809A1 (de) 1987-07-08
ZA864769B (en) 1987-02-25
IL79260A (en) 1990-11-29
JPS62503144A (ja) 1987-12-17
DK107787A (da) 1987-03-02
EP0227809A4 (de) 1987-10-19
EP0227809B1 (de) 1992-09-23
ATE80802T1 (de) 1992-10-15

Similar Documents

Publication Publication Date Title
ATE156517T1 (de) Antisens-oligonukleotide zur behandlung von krebs
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
ES8205231A1 (es) Procedimiento para preparar complejos de platino (iv)-diami-na
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
ZA832580B (en) N-glycosylated carboxamide derivatives,process for their preparation and their use for influencing the body's inherent defences
DE3686811D1 (de) Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
PH18031A (en) Immunoglobulin conjugates,process for preparing them and pharmaceutical composition containing the same
ES498476A0 (es) Procedimiento de preparacion de arn ribosomales bacterianos
FI104234B1 (fi) Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
ATE60037T1 (de) Verfahren zur herstellung eines werkstoffs aus silicium.
PT81093B (pt) Processo para a preparacao de uma composicao terapeutica para tratamento de um tumor
PT71408A (de) Verfahren zur herstellung von 1-alkadien-2,4-yl-2-hidroxymethyl-3,4,5-trimydroxypiperidinen mit wirkung uber die kohlehydraten und/oder fettwechsel und von diesen verbindungen enthaltenden pharmazeutischen und/oder tierartzleichen praparaten
ATE81499T1 (de) 2-acyloxypropylamin-derivate, verfahren zur herstellung und diese enthaltende arzneimittel.
ES2052635T3 (es) Nuevas silil alquilen aminas sustituidas.
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
ES8304582A1 (es) Procedimiento para preparar compuestos de estano.
DE69011065D1 (de) Verfahren zur Behandlung von Nickel-Magnesium-Silikaterzen.
DE60041266D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE95062T1 (de) Zusammensetzung zur behandlung von krebs, gekennzeichnet durch ueberexpression des c-fmsproto-onkogens.
ATE26468T1 (de) Verfahren zur waermebehandlung von gegenstaenden aus formgedaechtnislegierungen und gegenstaende nach diesem verfahren hergestellt.
IT8223703A0 (it) Procedimento di trattamento di micelio, in particolare derivato da processi di fermentazione dell'industria chimico-farmaceutica, per smaltimento ecologico.
ATE96980T1 (de) Verfahren zur herstellung von torfersatz, anlage zur durchfuehrung dieses verfahrens, anwendung des verfahrens und nach diesem verfahren hergestellter torfersatz.

Legal Events

Date Code Title Description
8332 No legal effect for de